Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23011158 | 0.93 | LMNA (0.53) | LMNATSHRCYP2C19MEN1CYP1A2 | |
| SCHEMBL1769341 | 0.91 | LMNA (0.64) | LMNATSHRCYP2C19MEN1CYP1A2 | |
| SCHEMBL12273135 | 0.88 | LMNA (0.68) | LMNATSHRCYP2C19MEN1CYP1A2 | |
| SCHEMBL3903075 | 0.85 | L3MBTL1 (0.58) | LMNATSHRCYP2C19MEN1CYP1A2 | |
| SCHEMBL6737966 | 0.85 | OPRM1 (0.67) | LMNATSHRCYP2C19MEN1CYP1A2 | |
| SCHEMBL23011352 | 0.83 | NPC1 (0.46) | LMNATSHRCYP2C19MEN1CYP1A2 | |
| SCHEMBL22992467 | 0.81 | OPRM1 (0.52) | LMNATSHRCYP2C19ALDH1A1OPRM1 | |
| SCHEMBL2324751 | 0.81 | OPRM1 (0.52) | LMNATSHRCYP2C19ALDH1A1HDAC1 | |
| SCHEMBL1625409 | 0.81 | OPRM1 (0.67) | LMNATSHRCYP2C19ALDH1A1OPRM1 | |
| SCHEMBL14731158 | 0.81 | OPRM1 (0.52) | LMNATSHRCYP2C19ALDH1A1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073485-A1 | Functionalised Amine Derivatives as IL-17 Modulators | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2022-03-10 | — | — | US | disclosed |
| EP-3894003-A1 | FUNCTIONALISED AMINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2021-10-20 | — | — | EP | disclosed |
| CN-113260418-A | Functionalized amine derivatives as IL-17 modulators | UCB生物制药有限责任公司 | 2021-08-13 | — | — | CN | disclosed |
| WO-2021027721-A1 | IMMUNOMODULATOR | 成都先导药物开发股份有限公司 | 2021-02-18 | — | — | WO | disclosed |
| WO-2020120141-A1 | FUNCTIONALISED AMINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-06-18 | — | — | WO | disclosed |
| US-9187453-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-02 | — | — | US | disclosed |
| EP-2832734-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073485-A1 | Functionalised Amine Derivatives as IL-17 Modulators | IL17A, IL15, IL2 | LMNA 4646/4885TSHR 1151/4885CYP2C19 98/4885 |
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | LMNA 2866/4885TSHR 744/4885CYP2C19 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.